Al Mutair, 538 patient favipiravir ICU study: 7% lower mortality [p=0.49], 9% higher ARDS [p=0.63], 34% longer ICU admission [p=0.001], and 37% longer hospitalization [p=0.001] https://c19p.org/almutair
copied to clipboard
Overview of Clinical Outcome and Therapeutic Effectiveness of Favipiravir in Patients with COVID-19 Admitted to Intensive Care Unit, Riyadh, Saudi Arabia
et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.01.013
Retrospective 269 favipiravir ICU patients in Saudi Arabia and 269 matched controls receiving different treatments, showing no significant difference.
|
risk of death, 7.0% lower, RR 0.93, p = 0.49, treatment 119 of 269 (44.2%), control 128 of 269 (47.6%), NNT 30.
|
|
risk of ARDS, 8.6% higher, RR 1.09, p = 0.63, treatment 76 of 269 (28.3%), control 70 of 269 (26.0%), severe ARDS.
|
|
ICU time, 33.7% higher, relative time 1.34, p = 0.001, treatment 269, control 269.
|
|
hospitalization time, 36.6% higher, relative time 1.37, p = 0.001, treatment 269, control 269.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Al Mutair et al., 15 Feb 2022, retrospective, Saudi Arabia, peer-reviewed, 14 authors, study period April 2020 - March 2021, this trial compares with another treatment - results may be better when compared to placebo.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.